查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884075

神经科药物市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032）

Neurology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

神经科药物市场成长因素

由于全球神经系统疾病的增加以及科学进步推动的治疗方法变革，全球神经科药物市场持续扩张。最新研究显示，在医疗保健支出成长、新药上市和神经诊断技术创新等因素的推动下，预计到2024年，该市场规模将达到824.7亿美元。随着治疗方法的广泛应用，预计到2025年，该市场规模将增长至872.6亿美元，并在生物製药、基因疗法和个人化医疗的快速发展推动下，到2032年将达到1,341.5亿美元。

神经系统药物对于控制阿兹海默症、帕金森氏症、癫痫、多发性硬化症和脑血管疾病等疾病至关重要。由于人口老化和诊断能力的提高，这些疾病的发生率都在上升。对基因研究、数位神经学工具和生物标记开发的投资不断增加，使得标靶治疗方案得以实现。诺华、拜耳、辉瑞和赛诺菲等领先的製药公司凭藉其广泛的产品组合、策略性收购和全球市场覆盖，保持着强大的市场地位。

市场动态

成长驱动因素

市场成长的主要驱动因素是神经系统疾病盛行率的不断上升。根据世界卫生组织（WHO，2024年）的预测，全球超过三分之一的人口将受到神经系统疾病的影响，将显着增加全球疾病负担。公众意识的提高和诊断手段的改善促进了早期发现，从而推动了对神经系统药物的需求。随着已开发国家和新兴国家人口老化，对长期神经系统照护的需求预计将显着增加。

抑制剂

高昂的治疗费用仍是市场扩张的主要障碍。神经系统治疗需要大量的研发、多阶段临床试验以及严格的监管审批，这推高了研发成本。最终，这推高了药品价格，给患者和医疗保健系统都带来了经济负担。例如，美国神经病学会报告称，2021年多发性硬化症的治疗费用将达到每年2,378美元，并且逐年增加。治疗费用不断上涨的趋势持续限制中低收入社区的药物负担能力。

趋势

技术进步正在改变市场。人工智慧辅助诊断、脑机介面 (BCI)、穿戴式装置、虚拟实境 (VR) 復健系统和先进的神经影像技术等工具正在改善疾病管理。基因疗法已成为治疗遗传性疾病的有力手段，而生物製剂和单株抗体因其标靶作用机制和副作用较小而发展迅速。在政府激励措施和独家市场权的支持下，对罕见神经系统疾病治疗的投资正在增加。

机会

个人化医疗的日益普及带来了巨大的机会。基于患者的基因资讯、生物标记和疾病机制的客製化治疗有望改善疗效并最大限度地减少副作用。这种转变正促使製药公司投资先进的药物设计和精准医疗。

挑战

神经系统疾病的复杂性带来了巨大的科学挑战。神经系统疾病通常是多因素的，其特征是患者反应各异且难以触及大脑中的标靶。药物难以穿过血脑屏障、发展中地区医疗基础设施有限以及罕见疾病患者招募困难等问题阻碍了药物研发进程。

市场区隔洞察

按适应症

由于阿兹海默症患者病率不断上升以及支持早期诊断和治疗的宣传活动日益增多，预计该疾病将推动市场成长。目前，美国约有720万人患有阿兹海默症。

随着各公司加强对新型疗法的研发力度，多发性硬化症市场预计将稳定成长。

依药物类别

由于使用率高且近期有新产品获批，胆碱酯酶抑制剂占了最大的市场占有率。 2021年，FDA批准了用于治疗阿兹海默症的药物ADUHELM，进一步巩固了这个细分市场。

由于新产品的上市和技术创新带来的改进，NMDA受体拮抗剂市场也不断扩张。

依给药途径

由于患者依从性高且易于长期使用，口服给药途径在2024年占主导地位。

随着更多生物製剂和标靶疗法进入市场，肠外给药途径预计将会成长。

按分销管道

由于处方率高且患者数量庞大，医院药局在2024年占了最大的市场占有率。

由于便利性和消费者便利性的提高，零售药局和网路药局预计将会成长。

区域展望

2024年，北美地区在神经系统药物市场占主导地位，市场规模达420.3亿美元（市占率50.96%）。美国在创新、先进疗法的早期应用以及高患者诊断率方面均处于领先地位。欧洲是第二大市场，这得益于其完善的医疗基础设施和较高的健康意识。亚太地区预计将以最快的速度成长，这主要受疾病盛行率上升、医疗投资增加以及中国和印度人口老化等因素的推动。拉丁美洲以及中东和非洲地区在健保报销体系和公共卫生政策的完善支持下，呈现稳定成长态势。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要神经系统疾病盛行率（按主要国家划分）
  • 主要国家的监管框架
  • 主要国家的报销情况
  • 主要公司的新产品上市及核准状况
  • 主要产业趋势（併购、合作等）等等）

第五章：全球神经系统药物市场分析、洞察与预测（2019-2032）

  • 依适应症划分的市场分析、洞察与预测
    • 阿兹海默症
    • 多发性硬化症
    • 癫痫
    • 帕金森氏症
    • 其他
  • 按药物类别划分的市场分析、洞察与预测
    • 胆碱酯酶抑制剂
    • NMDA受体拮抗剂
    • 抗惊厥药
    • 免疫调节剂
    • 其他
  • 依给药途径划分的市场分析、洞察与预测
    • 口服
    • 肠外给药
  • 按给药途径划分的市场分析、洞察与预测- 按分销管道
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测 - 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美神经系统药物市场分析、洞察与预测，2019-2032

  • 依国家/地区
    • 美国
    • 加拿大

第七章：欧洲神经系统药物市场分析、洞察与预测，2019-2032

  • 依国家/地区
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区神经系统药物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲神经系统药物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东东非和非洲神经病学药物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 南非
    • 海湾合作委员会
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 卫材株式会社
    • 策略
    • 百健公司
    • 拜耳公司
    • 辉瑞公司
    • 强生公司
    • 诺华公司
    • 默克集团
    • 赛诺菲
    • 艾伯维公司
Product Code: FBI113562

Growth Factors of neurology drugs Market

The global neurology drugs market continues to expand as neurological disorders become more prevalent worldwide and scientific advancements reshape therapeutic approaches. According to the latest findings, the market was valued at USD 82.47 billion in 2024, supported by rising healthcare spending, new drug launches, and technological innovations in neurological diagnostics. The market is projected to increase to USD 87.26 billion in 2025 as treatment adoption rises, and reach USD 134.15 billion by 2032, driven by rapid advancements in biologics, gene therapies, and personalized medicine.

Neurology drugs are essential for managing conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and cerebrovascular disorders, all of which are becoming more widespread due to aging populations and improved diagnosis capabilities. Increasing investments in genetic research, digital neurology tools, and biomarker development are enabling targeted therapeutic solutions. Prominent pharmaceutical companies-Novartis AG, Bayer AG, Pfizer Inc., and Sanofi-maintain strong positions due to extensive product portfolios, strategic acquisitions, and global market presence.

Market Dynamics

Drivers

A major driver of market growth is the increasing prevalence of neurological disorders. According to the WHO (2024), more than 1 in 3 individuals worldwide are affected by neurological conditions, indicating a substantial rise in the global disease burden. Growing awareness campaigns and improved access to diagnostics have enhanced early detection, driving higher demand for neurology medications. As populations in developed and emerging countries continue to age, the need for long-term neurological care is expected to rise significantly.

Restraints

The high cost of treatment remains a significant barrier to market expansion. Neurology drugs require extensive R&D, multi-phase clinical trials, and rigorous regulatory approvals, which increase development costs. This ultimately raises drug prices, placing financial pressure on both patients and healthcare systems. For instance, the American Academy of Neurology reported that multiple sclerosis treatment costs reached USD 2,378 annually in 2021, with expenses rising each year. Such increasing treatment burdens continue to limit affordability in low-income and middle-income regions.

Trends

The market is experiencing a transformative shift due to technological advancements. Tools such as AI-assisted diagnosis, brain-computer interfaces (BCIs), wearables, virtual reality (VR) rehabilitation systems, and advanced neuroimaging technologies are enhancing disease management. Gene therapies are emerging as powerful approaches for genetic disorders, while biologics and monoclonal antibodies are gaining momentum due to their targeted mechanism of action and reduced adverse effects. Investments in therapies for rare neurological diseases are increasing, supported by government incentives and exclusive marketing rights.

Opportunities

Growing adoption of personalized medicine presents significant opportunities. Tailored treatments based on patient genetics, biomarkers, and specific disease mechanisms are expected to improve outcomes and minimize side effects. This shift is driving pharmaceutical companies to invest in advanced drug design and precision-based therapies.

Challenges

The complexity of neurological disorders poses major scientific challenges. Neurological diseases are often multifactorial, with varied patient responses and difficult-to-access brain targets. Difficulties in drug delivery across the blood-brain barrier, limited healthcare infrastructure in developing regions, and challenges in patient recruitment for rare diseases impede drug development timelines.

Segmentation Insights

By Indication

Alzheimer's disease is projected to dominate the market due to rising prevalence and increasing awareness campaigns that support early diagnosis and treatment. The U.S. currently has approximately 7.2 million people living with Alzheimer's.

Multiple sclerosis is expected to grow steadily as companies intensify R&D for novel therapies.

By Drug Class

Cholinesterase inhibitors hold the largest share due to high usage and recent product approvals. The 2021 FDA approval of ADUHELM for Alzheimer's disease has strengthened the segment.

NMDA receptor antagonists are also expanding due to new launches and technology-driven improvements.

By Route of Administration

The oral segment dominated in 2024 due to high patient compliance and ease of long-term use.

The parenteral segment is expected to grow as more biologics and targeted therapies enter the market.

By Distribution Channel

Hospital pharmacies accounted for the largest share in 2024 due to higher prescription rates and greater patient inflow.

Retail and online pharmacies are projected to grow with increased accessibility and consumer convenience.

Regional Outlook

North America dominated the neurology drugs market in 2024, holding 50.96% market share, valued at USD 42.03 billion. The U.S. leads in innovation, early adoption of advanced therapies, and strong patient diagnosis rates. Europe is the second-largest market, supported by robust healthcare infrastructure and high awareness levels. The Asia Pacific region is expected to grow at the fastest pace, fueled by rising disease prevalence, healthcare investments, and growing elderly populations in China and India. Latin America and the Middle East & Africa show steady growth supported by improved reimbursement and public health initiatives.

Segmentation By Indication

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Parkinson's Disease
  • Others

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonist
  • Antiepileptic Drugs
  • Immunomodulatory Drugs
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

  • North America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Neurological Disorders, By Key Countries/Regions
  • 4.2. Regolatory Framework, By Key Countries/Regions
  • 4.3. Reimbursement Scenario, By Key Countries/Regions
  • 4.4. New Product Launches & Approvals, By Key Players
  • 4.5. Key Industry Developments (Merger, Acquisition, Collaboration, etc.)

5. Global Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Indication
    • 5.1.1. Alzheimer's Disease
    • 5.1.2. Moltiple Sclerosis
    • 5.1.3. Epilepsy
    • 5.1.4. Parkinson's Disease
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Cholinesterase Inhibitors
    • 5.2.2. NMDA Receptor Antagonist
    • 5.2.3. Antiepileptic Drugs
    • 5.2.4. Immunomodolatory Drugs
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Indication
    • 6.1.1. Alzheimer's Disease
    • 6.1.2. Moltiple Sclerosis
    • 6.1.3. Epilepsy
    • 6.1.4. Parkinson's Disease
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Cholinesterase Inhibitors
    • 6.2.2. NMDA Receptor Antagonist
    • 6.2.3. Antiepileptic Drugs
    • 6.2.4. Immunomodolatory Drugs
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Indication
    • 7.1.1. Alzheimer's Disease
    • 7.1.2. Moltiple Sclerosis
    • 7.1.3. Epilepsy
    • 7.1.4. Parkinson's Disease
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Cholinesterase Inhibitors
    • 7.2.2. NMDA Receptor Antagonist
    • 7.2.3. Antiepileptic Drugs
    • 7.2.4. Immunomodolatory Drugs
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Indication
    • 8.1.1. Alzheimer's Disease
    • 8.1.2. Moltiple Sclerosis
    • 8.1.3. Epilepsy
    • 8.1.4. Parkinson's Disease
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Cholinesterase Inhibitors
    • 8.2.2. NMDA Receptor Antagonist
    • 8.2.3. Antiepileptic Drugs
    • 8.2.4. Immunomodolatory Drugs
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. India
    • 8.5.3. Japan
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Indication
    • 9.1.1. Alzheimer's Disease
    • 9.1.2. Moltiple Sclerosis
    • 9.1.3. Epilepsy
    • 9.1.4. Parkinson's Disease
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Cholinesterase Inhibitors
    • 9.2.2. NMDA Receptor Antagonist
    • 9.2.3. Antiepileptic Drugs
    • 9.2.4. Immunomodolatory Drugs
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Neurology Drugs Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Indication
    • 10.1.1. Alzheimer's Disease
    • 10.1.2. Moltiple Sclerosis
    • 10.1.3. Epilepsy
    • 10.1.4. Parkinson's Disease
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Cholinesterase Inhibitors
    • 10.2.2. NMDA Receptor Antagonist
    • 10.2.3. Antiepileptic Drugs
    • 10.2.4. Immunomodolatory Drugs
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. South Africa
    • 10.5.2. GCC
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Eisai Co., Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT, etc.
    • 11.2.2. Strategies
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT, etc.
    • 11.2.3. Biogen Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT, etc.
    • 11.2.4. Bayer AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT, etc.
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT, etc.
    • 11.2.6. Johnson & Johnson Services, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT, etc.
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT, etc.
    • 11.2.8. Merck KGaA
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. Financials (Based on Availability)
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. SWOT, etc.
    • 11.2.9. Sanofi
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. Financials (Based on Availability)
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. SWOT, etc.
    • 11.2.10. AbbVie Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. Financials (Based on Availability)
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. SWOT, etc.

List of Tables

  • Table 1: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 2: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 3: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 4: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 5: Global Neurology Drugs Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 7: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 8: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 9: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 10: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 12: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 13: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 14: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 15: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 16: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 17: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 18: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 19: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 21: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 22: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 23: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 24: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 25: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 26: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2019-2032
  • Table 27: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2019-2032
  • Table 28: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 29: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032

List of Figures

  • Figure 1: Global Neurology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Neurology Drugs Market Value Share (%), By Indication, 2024 & 2032
  • Figure 3: Global Neurology Drugs Market Value Share (%), By Drug Class, 2024 & 2032
  • Figure 4: Global Neurology Drugs Market Value Share (%), By Route of Administration, 2024 & 2032
  • Figure 5: Global Neurology Drugs Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 6: Global Neurology Drugs Market Value (USD billion), by Region, 2024 & 2032
  • Figure 7: North America Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 8: North America Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 9: North America Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 10: North America Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 11: North America Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 12: North America Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 13: North America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: North America Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: North America Neurology Drugs Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Neurology Drugs Market Value Share (%), By Country, 2024
  • Figure 17: Europe Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 18: Europe Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 19: Europe Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 20: Europe Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 21: Europe Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 22: Europe Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 23: Europe Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 24: Europe Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 25: Europe Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 26: Europe Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 27: Asia Pacific Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 28: Asia Pacific Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 29: Asia Pacific Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 30: Asia Pacific Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 31: Asia Pacific Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 33: Asia Pacific Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 35: Asia Pacific Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 36: Asia Pacific Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 37: Latin America Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 38: Latin America Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 39: Latin America Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 40: Latin America Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 41: Latin America Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 42: Latin America Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 43: Latin America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 45: Latin America Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 46: Latin America Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 47: Middle East & Africa Neurology Drugs Market Value (USD billion), By Indication, 2024 & 2032
  • Figure 48: Middle East & Africa Neurology Drugs Market Value Share (%), By Indication, 2024
  • Figure 49: Middle East & Africa Neurology Drugs Market Value (USD billion), By Drug Class, 2024 & 2032
  • Figure 50: Middle East & Africa Neurology Drugs Market Value Share (%), By Drug Class, 2024
  • Figure 51: Middle East & Africa Neurology Drugs Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Neurology Drugs Market Value Share (%), By Route of Administration, 2024
  • Figure 53: Middle East & Africa Neurology Drugs Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Neurology Drugs Market Value Share (%), By Distribution Channel, 2024
  • Figure 55: Middle East & Africa Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 56: Middle East & Africa Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 57: Global Neurology Drugs Market Share (%), By Company, 2024